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Associations between Body Composition,  
Disease Activity and Quality of Life in Patients  
with Crohn’s Disease: A Cross-Sectional Study
Abstract
Background & Aims: Patients with Crohn’s disease (CD) treated with tumor necrosis factor-α (TNF-α) inhibitors are heterogeneous and 
respond differently to treatment. We aimed to investigate if disease activity and quality of life were associated with the individual varying 
distribution of fat and fat free mass.
Methods: A sample of 83 CD patients treated with TNF-α inhibitors were examined in this single center, cross-sectional study. Body 
composition was measured by bioelectrical impedance analysis (BIA) and muscle function by handgrip strength (HGS). The association to 
disease activity assessed by Harvey-Bradshaw Index (HBI), C- reactive protein (CRP) and quality of life assessed by Short Health Scale (SHS) 
was investigated.
Results: Increased fat mass index (FMI) was significantly associated to higher disease activity assessed by HBI (p < 0.05) and showed a 
trend toward a higher CRP level in multivariate non-parametric regression analyses (p=0.07). Univariate tests showed a significant positive 
association between FMI and SHS as well. Fat free mass index (FFMI) and HGS were not associated to disease activity or quality of life in this 
population.
Conclusion: Despite TNF-α inhibitor therapy, one third of the patients in this study experienced active disease. High FMI was significantly 
associated to increased disease activity and decreased quality of life. No associations were seen between FFMI, HGS and body composition. 
Larger studies are needed to confirm these results, and to investigate confounders.
Keywords: Crohn’s disease; Tumor necrosis factor alpha; Antagonists and inhibitors; Body composition; Disease activity; Quality of life; 
Adalimumab; Bioelectrical impedance analysis; Fat free mass index; Fat mass index; Infliximab; Pro-inflammatory cytokine; Adipocytes; 
Mesenteric fat; Skeletal muscle mass
Abbrevations: AAUH: Aalborg University Hospital; ADA: Adalimumab; BIA: Bioelectrical Impedance Analysis; BMI: Body Mass Index; CD: 
Crohn’s Disease; FFMI: Fat Free Mass Index; FMI: Fat Mass Index; HBI: Harvey-Bradshaw Index; HGS: Handgrip Strength; IFX: Infliximab; SHS: 
Short Health Scale; TNF-α: Tumor Necrosis Factor Alpha
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease, 
which is characterized by discontinuing, transmural, inflammato-
ry lesions, which can affect any part of the gastrointestinal tract. 
Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine 
and is often increased in patients with CD compared to healthy 
populations. The blockage of the TNF-α pathway using TNF-α in-
hibitors like Infliximab (IFX) and Adalimumab (ADA) has shown 
efficacy in treatment of CD [1]. However, between 23-46 % of all 
patients do not respond sufficiently to treatment with TNF-α in-
hibitors 12 months after initiation [2].
Adipocytes, especially those in mesenteric fat, have shown to 
be a source of TNF-α and there seem to be a correlation between 
distribution of fat tissue, the production of TNF-α and activity of 
disease [3]. A few studies have shown high body mass index (BMI) 
and body fat levels to be associated with reduced response to IFX 
[4] and that patients with high fat ratios required increased dos-
age of ADA [5].
Muscle mass has also been shown to affect progress of disease. 
In one study, high muscle mass ratio before surgery was correlated 
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to less postoperative complications [6]. Furthermore, loss of skel-
etal muscle mass has shown to be associated with poor response 
to TNF-α-inhibitor treatment [7,8].
Body composition parameters like fat and muscle mass are of-
ten altered in patients with CD [9], which might be explained by 
the symptoms of disease (diarrhea, reduced nutrition absorption 
etc.), the catabolic role of inflammation and by the frequent use of 
corticosteroids [1,10]. Especially weight- and muscle loss during 
disease activity are often seen. Treatment with TNF-α inhibitors 
have shown to improve muscle parameters in the same group of 
patients [1,11].
These findings give reason to investigate in further details, 
whether disease activity and quality of life are associated with 
the distribution of fat and muscle mass, which was the aim of this 
study.
Materials and Methods
Sampling
During a five-week recruitment period in 2017, 127 CD pa-
tients in IFX or ADA treatment were invited to participate in this 
cross-sectional study at Aalborg University Hospital (AAUH). Only 
patients in maintenance IFX or ADA therapy were included. Pa-
tients in induction regimes (first 8 weeks after initiation) were 
excluded. Exclusion criteria further consisted of pregnancies, limb 
prostheses, implanted electronic devices and inability to stand up, 
according to the bioelectrical impedance analysis (BIA) measure-
ment guidelines.
Measurement of body composition and muscle strength
Body composition was measured by BIA and performed with 
Tanita Body Composition Analyzer BC-418MA (Tanita corpora-
tion, Japan). Data gathered from BIA included BMI (kg/m2), fat 
mass index (FMI)(kg/m2) and fat free mass index (FFMI) (kg/
m2). Patients were instructed to fast at least 2 hours and to pass 
water latest 30 minutes before the BIA measurement. 
Hand grip strength (HGS), which is a functional objective cor-
related to muscle mass, was measured with SAEHAN® DHD-1 
Digital Hand Dynamometer (SAEHAN corporation, South. Korea, 
2013) [12]. Patients were encouraged to apply maximal pow-
er with their dominant hand 3 times with 15 seconds of rest in 
between. The maximal value for each patient was included in the 
study.
Assessment of disease activity and quality of life
As a standard approach to TNF-α-inhibitor therapy at AAUH, 
patients with CD complete a Harvey Bradshaw Index (HBI) and 
Short Health Scale (SHS) questionnaire on touch screens prior to 
treatment. These scores together with information about treat-
ment status and blood sample values (CRP, albumin, hemoglobin) 
are collected and stored in “Gastrobio”, a database developed by 
Department of Gastroenterology and Hepatology, AAUH [13]. HBI 
and SHS were used as subjective assessments of disease activity 
and quality of life, while CRP was used as an objective measure-
ment for disease activity. High values of HBI and CRP indicate 
more severe disease activity and high values of SHS indicate re-
duced quality of life. HBI ≥ 5 indicates active disease [14].
Statistical analysis
Results are presented as means with standard deviations 
(SD) for parametric data and as medians with interquartile rang-
es (IQR) for nonparametric data. Nominal data are presented as 
numbers (%). Uni- and multivariable non-parametric regression 
analyses were used to investigate the associations between dis-
ease activity (HBI and CRP), quality of life (SHS), body composi-
tion parameters (BMI, FMI, FFMI) and muscle function (HGS). 
Bootstrapping using 1000 replications were used to construct 
95% percentile confidence intervals (CI) for multivariable esti-
mates. A p-value < 0.05 was considered statistically significant. 
The software package STATA version 15.1 (Stata Corp LP, College 
Station, Texas) was used for statistical calculations [15]. 
Ethical considerations
This study did not cause any interventions to the current ther-
apy standards or expend of biological material. Thus, the ethical 
committee of North Jutland Region had no objections to the study. 
The Danish data protection agency was notified about the study. 
Patients gave verbal and written consents prior to the study.
Results
Patient characteristics
Table 1: Patient characteristics for the total population, n = 83
Demographic Information
Gender (men), n (%) 39 (47.0 %)
Age, years (SD) 37.3 (12.6)
Smoker, n (%) 19 (22.9 %)
Activity of Disease
Disease duration, years (SD) 11.2 (9.5)
HBI, median (IQR) 3 (1-5)
HBI ≥ 5, n (%) 25 (30.1 %)
SHS, median (IQR) 25 (12-48)
CRP, mg/L (SD) n=75 5.6 (12.2)
Treatment Status
Infliximab, n (%) 58 (70%)
Adalimumab, n (%) 25 (30. %)
Treatment duration, years (SD) 5.3 (4.0)
Combination therapy
Azathioprine/Methotrexate, n (%) 43 (51.8%)
Corticosteroids, n (%) 6 (7.2%)
Body Composition
Weight, kg (SD) 76.9 (14.1)
BMI, kg/m2 (SD) 25.4 (4.5)
Fat mass index, kg/m2 (SD) 7.5 (3.8)
Fat free mass index, kg/m2 (SD) 17.9 (2.3)
Handgrip strength, kg (SD) n=82 42.7 (11.3)
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In total 127 patients were invited during the inclusion period. 
Seven were excluded according to the BIA measurement guide-
lines. Out of the remaining 120 patients, 83 patients (69 %) with 
a mean age of 37.3 (±12.6) years accepted to participate and suc-
cessfully completed the examination. Of these, 39 were men (47 
%). Mean duration of disease and treatment were 11.2 (±9.5) and 
5.2 (±4.0) years respectively. Of all patients, 25 (30.1 %) were in 
active disease according to HBI ≥ 5. Median HBI was 3 (IQR 1-5), 
mean CRP was 5.58 (±12.2) g/L and median SHS was 25 (IQR 12-
48). Mean values for body composition parameters were BMI 25.4 
(±4.5 kg/m2), FMI 7.5 (±3.8) kg/m2, FFMI 17.9 (±2.3) kg/m2 and 
HGS 42.7 (±11.3) kg. Full list of main characteristics of the study 
population is presented in Table 1. 
Associations between body composition, disease activity and quality of life
Table 2: Non-parametric regression analysis between body composition (BMI, FMI, FFMI and HGS), disease activity (HBI and CRP) and quality 
of life (SHS).
HBI CRP SHS
Coefficient p-Value Coefficient p-Value Coefficient p-Value
BMI 0.29 0.01 0.31 0.17 0.98 0.05
Fat Mass Index 0.42 0.004 0.6 0.07 1.27 0.04
Fat Free Mass 
Index 0.09 0.74 -0.56 0.73 0.06 0.95
HGS -0.01 0.89 -0.13 0.23 0.26 0.31
Univariate non-parametric regression analyses were used to 
investigate any associations between disease activity, quality of 
life and body composition parameters. Table 2 shows associa-
tions. In our population high values of BMI were associated with 
significantly higher scores on HBI (coefficient 0.29, p= 0.01) and 
SHS (coefficient 0.98, p 0.05) indicating more severe disease ac-
tivity and less quality of life. Likewise, high values of FMI were as-
sociated with significantly higher scores on HBI (coefficient 0.042, 
p= 0.004) and SHS (coefficient 1.27, p= 0.04), indicating the same 
pattern. Further, a trend between high values of FMI and CRP was 
observed, but did not show any significance (coefficient 0.60, p= 
0.07). FFMI and HGS were not associated to body composition pa-
rameters.
Table 3: Multivariate analysis of associations between body composition (BMI, FMI, FFMI and HGS), disease activity (HBI and CRP) and quality of 
life (SHS). *95% confidence intervals (95% CI) and p-values were calculated using bootstrap-corrected analysis.
HBI CRP SHS
Coefficient (95% CI)* p-Value Coefficient (95% CI)* p-Value Coefficient (95% CI)* p-Value
BMI -0.04 (-0.38 to 0.33) 0.82 -0.58 (-1.51 to 0.21) 0.19 0.22 (-1.67 to 2.62) 0.84
Fat mass index 0.46 (0.08 to 0.86) 0.02 1.21 (-0.01 to 2.56) 0.07 1.04 (-1.68 to 3.15) 0.41
Multivariate non-parametric regression analyses performed 
between body composition parameters (BMI, FMI, FFMI and HGS) 
and the outcome variables (HBI, CRP and SHS) confirmed the sig-
nificant association between FMI and HBI (coefficient 0.46, p= 
0.02) and the non-significant trend between FMI and CRP (coeffi-
cient 1.21, p= 0.07). Conversely, no significance was seen between 
BMI, SHS and HBI. Neither did SHS and FMI show significance in 
multivariate regression analysis. See Table 3.
Discussion
This study aimed to investigate the associations between body 
composition, disease activity and quality of life in CD patients 
treated with TNF-α inhibitors. Multivariate analysis found FMI to 
be significantly associated with disease activity assessed by HBI 
and in univariate analysis to be significantly associated with qual-
ity of life assessed by SHS. BMI was significantly associated to HBI 
and SHS by univariate analyses, but not in multivariate analysis. 
FFMI and HGS showed no associations to neither disease activity 
nor quality of life in this study.
One third (n = 25, 30.1 %) of all patients included in this study 
scored HBI ≥ 5, indicating signs of active disease. This prevalence 
corresponds with the findings from a review by Ben-Horin et al. 
[2] which reports primary non-response to occur in 10-40 % and 
secondary non-response to occur in 23-46 % of all patients treat-
ed with TNF-α-inhibitors.
FMI and BMI were significantly associated to disease activity 
in the form of HBI in univariate analysis, but only FMI showed to 
be significant in multivariate analysis. This could be explained by 
the fact that BMI is highly affected by FMI and therefore showed 
no independent significance. 
High BMI and body fat have earlier been associated to poor 
response to IFX treatment and fatty tissues have shown to be a 
source of pro-inflammatory cytokines such as TNF-α and CRP 
[3,4]. Peyrin-Biroulet et al. [16] further found mesenteric fat as an 
important source of CRP-elevation in CD and that the local pro-
duction of CRP from mesenteric adipocytes might be stimulated 
by local inflammation in CD. Increased body fat and from this, in-
creased mesenteric fat, could be an explanation to the increased 
disease activity assessed by HBI in the more obese patients in this 
study. This association between high fat mass and inflammation 
has been shown in former studies as well [5,17,18].
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An eventual poor response to TNF-α-inhibitor therapy in pa-
tients with increased FMI besides the possible pro-inflammatory 
role of fat, could be the distribution of drug into fat tissues leading 
to a larger volume of distribution and thus lower drug concentra-
tion. IFX is administered intravenously, and Scaldaferri et al. [4] 
suggest that IFX does not distribute into adipose tissue. ADA on 
the other hand is administered subcutaneously and pharmacoki-
netics could be altered in the more obese patients [5,19].
CRP was used as an objective measurement of disease activity 
and showed a non-significant trend towards higher FMI in univar-
iate and multivariate test. This might indicate that high FMI was 
not only associated to higher HBI, which is a subjective assess-
ment of disease activity, but also to objective measurements of dis-
ease activity like CRP. Despite no significance, disease activity was 
negatively associated to FFMI and HGS pointing towards increased 
FFMI being a protective factor against increased disease activity as 
suggested by Zhang et al. [6] However, the lack of significance may 
be due to the relatively low sample size in this study.
Stjernman et al. [20] have concluded that SHS is a valid, reli-
able and responsive tool to quantify health related quality of life 
in CD patients. No investigations have been made regarding the 
relationship between body composition and health related quality 
of life in CD patients. In our findings, SHS was only significantly 
associated to FMI in univariate analysis, indicating a high FMI as-
sociated to reduced quality of life. Multivariate analysis showed 
no significance, making the association unclear and a topic for fur-
ther investigation. 
In this study, body composition was analyzed by the use of BIA, 
which is a cheap, non-invasive and fairly sensitive tool. However, 
other methods like DEXA, CT and MRI scans are more accurate 
and provide direct measurement of fat mass and fat free mass in-
cluding the distinction between mesenteric and subcutaneous fat 
levels [8,11].  The BIA equipment used in this study did not allow 
to distinguish between different types of fat and no further inves-
tigations into the pro-inflammatory role of mesenteric fat could be 
made. The benefit of CT and MRI scans is that many patients have 
gone through a CT or MRI scan as part of their treatment of CD, 
which provides the opportunity for a retrospective study design 
investigating the associations between disease activity, body com-
position and quality of life in a larger population.
Conclusion 
The purpose of this cross-sectional study was to explore if 
body composition in patients with CD treated with TNF-α in-
hibitors was associated to disease activity and quality of life. We 
found that almost one third of the patients showed signs of active 
disease, despite TNF-α inhibitor treatment. High FMI showed a 
significantly higher disease activity assessed by HBI and a trend 
towards higher CRP. This could indicate a pro-inflammatory role 
of fat and should be investigated further. FMI was also associated 
to poorer quality of life assessed by SHS, but only in univariate 
tests indicating more factors to influence this association as well. 
FFMI and HGS were not associated to neither disease activity nor 
quality of life.
Acknowledgements 
Mads Hilligsøe, Niklas D Eriksen, Maria H Jacobsen, Liv H 
Kaagaard and Mette Holst were responsible for the study design, 
data collection and analysis, drafted the manuscript and wrote the 
final edition. Henrik H Rasmussen and Lars Vinter-Jensen provid-
ed scientific guidance and medical expertise, contributed to the 
analysis and critically reviewed the manuscript.
The authors would like to thank participants, Tove Nygaard, 
Lotte Julin Hansen at Department of Gastroenterology, AAUH for 
providing the logistics and Department of Health Information, 
AAUH for sharing their facilities. A special thanks to Lone Larsen, 
Consultant MD, PhD stud., for extensive help regarding the Gastro-
bio database.
References
1. Csontos ÁA, Molnár A, Piri Z, Katona B, Dakó S, et al. (2016) The Effect 
of anti-TNFα induction therapy on the nutritional status and dietary 
intake in inflammatory bowel disease. J Gastrointest Liver Dis 25(1): 
49-56. 
2. Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF 
treatments in inflammatory bowel disease. Autoimmun Rev 13(1): 24-
30. 
3. Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa 
A, et al. (2010) Proinflammatory cytokines Il-6 and TNF-α and the 
development of inflammation in obese subjects. Eur J Med Res 
15(Suppl 2): 120-122. 
4. Scaldaferri F, D’Ambrosio D, Currò D, Petito V, Pecere S, et al. (2015) Role 
of BMI, use of immune suppressant and pharmacokinetic of infliximab-
pathway in determining prospective and retrospective response to 
the drug in cohort of IBD patients under maintenance therapy with 
infliximab. Dig Liver Dis 12(10): e0186575. 
5. Bultman E, De Haar C, Van Liere-Baron A, Verhoog H, West RL, et al. 
(2012) Predictors of dose escalation of adalimumab in a prospective 
cohort of Crohn’s disease patients. Aliment Pharmacol Ther 35(3): 
335-341. 
6. Zhang W, Zhu W, Ren J, Zuo L, Wu X, et al. (2015) Skeletal Muscle 
Percentage: A Protective Factor for Postoperative Morbidity in Crohn’s 
Disease Patients with Severe Malnutrition. J Gastrointest Surg 19(4): 
715-721. 
7. Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT (2015) Low 
muscle mass at treatment initiation is associated with early loss 
of response to anti-TNF therapy for Inflammatory Bowel Disease. J 
Gastroenterol Hepatol 30: 131. 
8. Ding NS, Malietzis G, Lung PF, Yip W, Penez L (2016) Body composition: 
A biomarker of therapeutic outcome in patients with Crohn’s disease. 
J Crohn’s Colitis. N.S. Ding, St Mark’s Hospital, IBD, London, United 
Kingdom, 10: S402-403. 
9. Back IR, Marcon SS, Gaino NM, Salate D, Vulcano B, et al. (2017) Body 
composition in patients with Crohn’s disease and ulcerative colitis. Arq 
Gastroenterol 54(2): 109-114.
10. Wiroth JB, Filippi J, Schneider SM, Al-Jaouni R, Horvais N, et al. (2005) 
Muscle performance in patients with Crohn’s disease in clinical 
remission. Inflamm Bowel Dis 11(3): 296-303. 
11. Emerenziani S, Biancone L, Guarino MPL, Balestrieri P, Stasi E, et al. 
(2016) Nutritional status and bioelectrical phase angle assessment in 
Advanced Research in Gastroenterology & Hepatology 
How to cite this article: Hilligsøe M, Eriksen ND, Jacobsen MH, Kaagaard LH, Rasmussen HH, et al. Associations between Body Composition, Disease 
Activity and Quality of Life in Patients with Crohn’s Disease: A Cross-Sectional Study. Adv Res Gastroentero Hepatol. 2019; 12(5): 555848. 
DOI:  10.19080/ARGH.2019.12.555848.
00102
Your next submission with JuniperPublishers    
      will reach you the below assets
• Quality Editorial service
• Swift Peer Review
• Reprints availability
• E-prints Service
• Manuscript Podcast for convenient understanding
• Global attainment for your research
• Manuscript accessibility in different formats 
         ( Pdf, E-pub, Full Text, audio) 
• Unceasing customer service
Track the below URL for one-step submission 
             https://juniperpublishers.com/online-submission.php
This work is licensed under Creative
Commons Attribution 4.0 License
DOI: 10.19080/ARGH.2019.12.555848
adult Crohn disease patients receiving anti-TNFα therapy. Dig Liver Dis 
49(5): 495-499. 
12. Lu ZL, Wang TR, Qiao YQ, Zheng Q, Sun Y, et al. (2016) Handgrip 
Strength Index Predicts Nutritional Status as a Complement to Body 
Mass Index in Crohn’s Disease. J Crohn’s Colitis 10(12): 1395-1400. 
13. Larsen L, Drewes AM, Fallingborg J, Jacobsen BA, Jess T (2016) Touch 
screens as a tool in patient care in the IBD outpatient clinic. Scand J 
Gastroenterol 51(9): 1106-1110. 
14. (2010) Inc. J. Harvey-Bradshaw Index (HBI) - A simple index of 
Crohn’s disease activity. British Columbia Ministry of Health Services. 
Worksheet based on the Harvey-Bradshaw Index. British Columbia 
Ministry of Health Services website. 
15. Brandse JF, Vos LMC, Jansen J, Schakel T, Ponsioen CIJ, et al. (2015) 
Serum concentration of Anti-TNF antibodies, adverse effects and 
quality of life in patients with inflammatory bowel disease in remission 
on maintenance treatment. J Crohn’s Colitis 9(11): 973-981. 
16. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, 
et al. (2012) Mesenteric fat as a source of C reactive protein and as a 
target for bacterial translocation in Crohn’s disease. Gut 61(1): 78-85. 
17. Ordás I, Feagan BG, Sandborn WJ (2012) Therapeutic Drug Monitoring 
of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease. 
Clin Gastroenterol Hepatol 10(10): 1079-1087. 
18. Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA (2014) 
Therapeutic drug monitoring in patients with inflammatory bowel 
disease. World J Gastroenterol 20(13): 3475-3484. 
19. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the 
pharmacokinetics of drug in humans. Clin pharmacokinet 49(2): 71-
87.
20. Stjernman H, Granno C, Jarnerot G, Ockander L, Tysk C, et al. (2008) 
Short health scale: A valid, reliable, and responsive instrument for 
subjective health assessment in Crohn’s disease. Imflamm Bowel Dis 
14(1): 47-52.
